Terms: = Thyroid cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA
1944 results:
1. dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe.
Rodrigues JS; Chenlo M; Bravo SB; Perez-Romero S; Suarez-Fariña M; Sobrino T; Sanz-Pamplona R; González-Prieto R; Blanco Freire MN; Nogueiras R; López M; Fugazzola L; Cameselle-Teijeiro JM; Alvarez CV
Nat Commun; 2024 May; 15(1):3736. PubMed ID: 38744818
[TBL] [Abstract] [Full Text] [Related]
2. [Interpretation of the pathological diagnostic criteria and characteristics of high-grade thyroid follicular-derived carcinoma in the 5
Zhou J; Liu ZY
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1578-1583. PubMed ID: 38742344
[TBL] [Abstract] [Full Text] [Related]
3. Next-generation sequencing identified that RET variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinoma.
Huang Y; Lin P; Liao J; Liang F; Han P; Fu S; Jiang Y; Yang Z; Tan N; Huang J; Chen R; Ouyang N; Huang X
BMC Endocr Disord; 2024 May; 24(1):68. PubMed ID: 38734621
[TBL] [Abstract] [Full Text] [Related]
4. Columnar Cell thyroid Carcinoma: A Heterogeneous Entity Demonstrating Overlap Between Papillary thyroid Carcinoma and Follicular Neoplasms.
Higgins KE; Sadow PM; Johnson DN; Wang P; Wanjari P; Cipriani NA
Head Neck Pathol; 2024 May; 18(1):39. PubMed ID: 38727854
[TBL] [Abstract] [Full Text] [Related]
5. [Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer].
Altena R; Nilsson M; Bergman V; Dahlberg J; Christofer Juhlin C; Zedenius J
Lakartidningen; 2024 Feb; 121():. PubMed ID: 38712675
[TBL] [Abstract] [Full Text] [Related]
6. A comparison of cardiovascular disease, cancer, mortality, and Graves' ophthalmopathy following treatment for hyperthyroidism: A Bayesian network meta-analysis.
Liu X; Wong CKH; Wu T; Chan WWL; Woo YC; Lam CLK; Lang BHH
World J Surg; 2024 Feb; 48(2):393-407. PubMed ID: 38686801
[TBL] [Abstract] [Full Text] [Related]
7. Promising Approaches in Plant-Based Therapies for thyroid cancer: An Overview of In Vitro, In Vivo, and Clinical Trial Studies.
Kaczmarzyk I; Nowak-Perlak M; Woźniak M
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674046
[TBL] [Abstract] [Full Text] [Related]
8. A zebrafish xenotransplant model of anaplastic thyroid cancer to study tumor microenvironment and innate immune cell interactions in vivo.
Michael C; Mendonça-Gomes JM; DePaolo CW; Di Cristofano A; de Oliveira S
Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38657656
[TBL] [Abstract] [Full Text] [Related]
9. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
[TBL] [Abstract] [Full Text] [Related]
10. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
[TBL] [Abstract] [Full Text] [Related]
11. Development and validation of prediction models for papillary thyroid cancer structural recurrence using machine learning approaches.
Wang H; Zhang C; Li Q; Tian T; Huang R; Qiu J; Tian R
BMC Cancer; 2024 Apr; 24(1):427. PubMed ID: 38589799
[TBL] [Abstract] [Full Text] [Related]
12. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ata initial and dynamic risk assessment.
Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of ultrasound risk stratification systems for pediatric thyroid nodules.
Yu J; Cui Y; Fu C; Ma X; Si C; Huang Y; Cui K; Zhang Y
Front Endocrinol (Lausanne); 2024; 15():1350123. PubMed ID: 38572472
[TBL] [Abstract] [Full Text] [Related]
14. Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation.
Zhang K; Wang X; Wei T; Li Z; Zhu J; Chen YW
Front Endocrinol (Lausanne); 2024; 15():1347362. PubMed ID: 38544687
[TBL] [Abstract] [Full Text] [Related]
15. The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies.
Hicks HM; Nassar VL; Lund J; Rose MM; Schweppe RE
Cancer Biol Ther; 2024 Dec; 25(1):2332000. PubMed ID: 38521968
[TBL] [Abstract] [Full Text] [Related]
16. Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics.
Hu J; Liu K; Ghosh C; Khaket TP; Shih H; Kebebew E
J Exp Clin Cancer Res; 2024 Mar; 43(1):85. PubMed ID: 38500204
[TBL] [Abstract] [Full Text] [Related]
17. BUB1/KIF14 complex promotes anaplastic thyroid carcinoma progression by inducing chromosome instability.
Jin T; Ding L; Chen J; Zou X; Xu T; Xuan Z; Wang S; Chen J; Wang W; Zhu C; Zhang Y; Huang P; Pan Z; Ge M
J Cell Mol Med; 2024 Apr; 28(7):e18182. PubMed ID: 38498903
[TBL] [Abstract] [Full Text] [Related]
18. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
[TBL] [Abstract] [Full Text] [Related]
19. Tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: an effective analysis based on real-world retrospective studies.
Kuang BH; Zhang WX; Lin GH; Fu C; Cao RB; Wang BC
Front Endocrinol (Lausanne); 2024; 15():1345203. PubMed ID: 38469143
[TBL] [Abstract] [Full Text] [Related]
20. The value of multimodal treatment in anaplastic thyroid cancer patients with distant metastasis.
Guo H; Lin H
BMC Surg; 2024 Mar; 24(1):79. PubMed ID: 38438944
[TBL] [Abstract] [Full Text] [Related]
[Next]
